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PERSPECTIVE
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Inflammation is a complex response of the host to tissue
injury, such as infection or physical insult (1). The main role
of inflammation is to quickly eliminate pathogens by initiating an adaptive immune response through stimulation of
antigen-specific T- and B-lymphocytes and their regulating
immune-transmitters, the pro-inflammatory cytokines. Cytokines are divided into predominantly pro-inflammatory and
predominantly anti-inflammatory types (2). Pro-inflammatory
cytokines, such as interleukin-6 (IL-6) and tumor necrosis
factor-alpha (TNF-alpha), are secreted by monocytes and
macrophages and activate other cellular components of the
inflammatory response. Anti-inflammatory cytokines, such
as interleukin-4 (IL-4), help to down-regulate the inflammatory immune response.
The role of inflammation in schizophrenia has received
intense attention and a cytokine-mediated mechanism represents the keystone of a number of hypotheses formulated
in the past two decades (2-4). The macrophage T-lymphocyte
hypothesis postulates that chronically activated macrophages
produce cytokines, such as interleukin-1 (IL-1), interleukin-2
(IL-2), tumor necrosis factors, interferon-alpha and interferongamma (5). The “T helper hypothesis” advances the idea of
a shift away from cytotoxic cell immune function toward
humoral immune reactivity (6). The microglia hypothesis
argues that pro-inflammatory cytokines and free radicals
are released by activated central nervous system microglia,
causing abnormal neurogenesis, neural degradation and
white matter abnormalities, which are known to play a role
in the pathogenesis of schizophrenia (7). A convergence
between neuroinflammatory changes and dopamine and
glutamate receptors has also been postulated, and clinical
trials with biological therapies developed for the reduction
of inflammation (8,9) and for autoimmune disorders (10,11)
are seriously considered.
The significance of cytokine abnormalities and other
markers of immune dysfunction identified in patients with
schizophrenia can be examined through the prism of
Bradford Hill’s guidelines (12), a widely accepted model
for judging whether an association can contribute to cause
a pathological phenomenon. Based on this framework, we
evaluate here the strength of the association; its consistency
in studies performed by different investigators on different
samples; its temporality, by trying to determine whether the

inflammation has preceded the onset of schizophrenia; its
biological gradient, meaning that the severity of schizophrenia should correlate with the magnitude of the inflammatory process; its plausibility as a pathophysiological
mechanism; the coherence between epidemiological and
laboratory findings; and the specificity of inflammatory
abnormalities.

STRENGTH AND CONSISTENCY
A thorough review of 40 studies of cytokine alterations
in schizophrenia has indicated substantial inter-observer
agreement with regard to the magnitude of increase in
the levels of IL-6, soluble IL-2 receptor and TNF-alpha
in first-episode psychosis and acutely relapsed inpatients
compared to healthy controls (3). For example, effect
sizes in drug-na€ıve, first-episode patients were 0.81 for
TNF-alpha, 1.03 for the soluble IL-2 receptor and 1.40 for
IL-6. Other cytokines (IL-1 beta, transforming growth
factor-beta, interferon-gamma and IL-12) had somewhat
lower effect sizes.

TEMPORALITY
Cytokine levels and other biomarkers of inflammation
have not been longitudinally assessed prior to the clinical
recognition of schizophrenia. Therefore, there is no direct
proof for a premorbid pathological phenotype. A temporal correlation has been suggested in a few small scale
studies, which have shown abnormal levels of interferongamma (13), soluble IL-2 receptor (14,15) and IL-6, and
TNF-alpha elevations (15) in patients with schizophrenia
and, to a lower extent, in their relatives compared to
healthy controls.

BIOLOGICAL GRADIENT
A biological gradient correlating levels of pro-inflammatory cytokines and severity of schizophrenia has not been
convincingly demonstrated. The correlation between the
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cytokines IL-1 beta, IL-6, IL-9, and TNF-beta with Positive
and Negative Syndrome Scale (PANSS) total and positive
scores identified in a cross-sectional study became insignificant after correcting for multiple comparisons, and no correlation was found with the negative symptoms subscale
scores (16).
The trajectories of cytokine levels after treatment appear
to be different in first-episode psychosis as compared to
schizophrenia in relapse (17). Meta-analytic data show that
the levels of some cytokines (IL-6, IL-1 beta, and transforming growth factor-beta) return to normal after antipsychotic
treatment, while the levels of others (TNF-alpha, soluble
IL-2 receptor, IL-12) remain elevated after the symptoms of
an acute exacerbation are controlled (3). This heterogeneity
has been interpreted to indicate that levels of different
cytokines may be either trait or state markers (3). The construct has not been proven to have specificity for schizophrenia, but rather for psychotic features (18).
Longitudinal studies of blood auto-antibodies in schizophrenia have also failed to indicate a biological gradient.
The proportion of patients with positive titers for anticardiolipin antibodies measured at the time of an acute
illness exacerbation and again after improvement following
antipsychotic drug treatment were 19.3% vs. 23.8% (p50.62)
for IgG and 15.8% vs. 26.2% (p50.22) for IgM, and titers
were negatively correlated with the PANSS positive subscale
scores (19).

COHERENCE
From an epidemiological standpoint, the relationship
between inflammation and schizophrenia has been investigated only in Denmark, in a nationwide study on the risk of
autoimmune disease in individuals with a personal or family
history of schizophrenia (20).
The incidence rate ratios indicated an association between schizophrenia and relatively infrequent conditions,
such as autoimmune hepatitis, Guillain-Barre syndrome,
multiple sclerosis, primary biliary cirrhosis, and pernicious
anemia. On the other hand, the incidence of schizophrenia
was lower than expected among patients with more common and undisputedly autoimmune conditions, such as
seropositive rheumatoid arthritis, polymyalgia rheumatica,
ankylosing spondylitis and autoimmune thyroiditis. The
incidence rate ratio for seropositive rheumatoid arthritis at
the onset of psychotic disorder was 0.75 and decreased to
0.60 five years later.
In the same study, some results are at odds with a clear
relationship between inflammation and schizophrenia. For
example, schizophrenia was found to be more frequently
present in people with Crohn’s disease compared to the general population, while at the same time being substantially
less frequent in those with ulcerative colitis (20).

SPECIFICITY
PLAUSIBILITY
This potential attribute can be inferred from trials of antiinflammatory drugs as adjunctive therapies in schizophrenia.
In a recent meta-analysis of cyclo-oxygenase-2 inhibitors
and aspirin given adjunctively with antipsychotic drugs,
including 8 studies (N5774 patients), the mean effect size
for the PANSS positive subscale scores was 20.189 and the
upper limit of the 95% confidence interval was 20.005, suggesting that the outcome of the intervention for this type of
symptoms was minimal/small (8). Moreover, the mean
effect sizes for PANSS total and negative symptoms scores
were non-significant.
A meta-regression analysis of the data indicated an
inverse relationship between the severity of negative symptoms at baseline and the efficacy of treatment with nonsteroidal anti-inflammatory drugs, a finding that argues for
the absence of a biological gradient and reduces even further the plausibility of a role for inflammation in determining the severity of schizophrenia. Nevertheless, effect sizes
for total PANSS scores were larger in trials of aspirin and in
studies with more first-episode patients (8).
Another recent exploratory meta-analysis found that
estrogens and N-acetyl cysteine had small to moderate
effect sizes when added to antipsychotics for PANSS total
symptoms (9).

190

There is no evidence for specificity of elevated proinflammatory cytokines or auto-antibodies, as similar findings have been observed in other psychiatric disorders.
Pro-inflammatory markers are strongly and consistently
associated with depression. For example, in a meta-analysis
of 25 studies of clinically depressed patients and healthy controls, the effect size of IL-6 was 0.71, and the 95% confidence
interval ranged from 0.46 to 0.97 (21). The association
remained significant after correction for comorbid somatic
disorders that could correlate with immune dysfunction,
such as cancer, and for treatment with antidepressant drugs,
which may reduce the release of pro-inflammatory cytokines
from activated microglia (22).
An expanded survey confirmed the significantly higher
concentrations of IL-6 and TNF-alpha in depressed patients
compared to healthy controls, and the effect size did not
appear to be influenced by the type of ELISA assay used (23).
Recent data also indicate that treatment with antidepressants reduces the levels of biomarkers of inflammation (24).
There is also evidence, generated in four placebo-controlled
trials, that treatment with the anti-inflammatory drug celecoxib, a cyclo-oxygenase-2 inhibitor, leads to greater mean
reductions in the Hamilton Rating Scale for Depression and
to significantly higher remission rates than placebo (25).
Increased levels of pro-inflammatory cytokines have
been shown to correlate with the severity of depression, and
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levels of IL-6 and TNF-alpha were higher in depressed
patients with suicidal ideation or attempts (26).
However, in random effects and fixed effects meta-analytic
models, the improvement of depressive symptoms did not
correlate with a change in serum levels of TNF-alpha, and
the biological gradient of IL-6 was very small (27). Subgroup
analyses suggested that, in contrast to other classes of antidepressant drugs, serotonin reuptake inhibitors may decrease
TNF-alpha and IL-6 levels, but such effects did not influence
the proportion of patients achieving a 50% reduction in
depressive symptoms.
The plausibility and coherence of these findings have remained relatively weak. For instance, although clinically
depressed patients have a higher expression of autoimmune
abnormalities, as reflected in the titers of anti-phospholipid
antibodies, there is a much lower incidence of positive patients
than in systemic lupus erythematosus, a classical autoimmune
disorder (28). Age and gender may be stronger determinants of
the titers of auto-antibodies than the type of affective disorder,
affective state or psychotropic medication (29). On the other
hand, in contrast with schizophrenia, the development of
depression-like behavior can be studied in experimental models and has been shown to be related to a cell-mediated
immune response (30).
Cytokine alterations similar to those found in schizophrenia have also been identified in patients with bipolar
disorder. A meta-analysis of 30 studies has found significant
elevations of IL-6, soluble IL-2 receptor and TNF-alpha
in bipolar patients compared to healthy controls (31). For
IL-6, the difference was primarily due to the immune changes
present during acute mania, as levels were normal in bipolar
depressed and euthymic patients. The levels of TNF-alpha
were similarly elevated in manic and depressed patients, and
a biological gradient, i.e., normalization during periods of
euthymia, was not observed.

whilst adipose tissue from lean individuals may preferentially secrete anti-inflammatory adipokines (including adiponectin, IL-10, IL-4 and IL-13), obesity is associated with
increased levels of pro-inflammatory cytokines (such as
TNF-alpha, leptin, plasminogen activator inhibitor, IL-6,
IL-1 beta) (34), coupled with a reduction in the secretion of
anti-inflammatory adipokines (35-39). Moreover, psychological stress may activate inflammatory responses in the
brain (40). Both chronic and acute stress have been
associated with increased production of pro-inflammatory
cytokines, including IL-6 and C-reactive protein (41), and
decreased levels of anti-inflammatory ones (42).
Overall, the review of currently available data suggests
that there is insufficient evidence that the replicated, strong
association between schizophrenia and elevated inflammatory markers has etiopathological relevance. Future studies
need to follow patients from the attenuated psychosis
syndrome to full-blown schizophrenia, and measure inflammatory cytokine levels in those patients who convert to psychosis and those who do not.
Since inflammation might be triggered by many factors,
including weight gain/obesity and psychological stress, both
cross-sectional and longitudinal studies of pro-inflammatory
cytokine levels in schizophrenia need to control for these
factors. Such studies should investigate the possibility that
non-specific inflammatory changes may influence the expression of psychosis and other severe mental disorders.
Should such inflammatory triggering of psychopathology
occur, at least in subgroups of patients or in specific phases
of the illness, the finding could clearly lead to novel treatment approaches.
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The application of Bradford Hill’s criteria for distinguishing association from causation with regard to increased
pro-inflammatory cytokines in schizophrenia finds robust
evidence for strength and consistency. However, a biological gradient has not been convincingly demonstrated and
there is no direct proof of temporality. Fulfillment of the
criteria for plausibility and coherence is modest, at best.
Most importantly, the association lacks specificity, because
similar or stronger correlations have been reported in major
depression and bipolar disorder.
We believe that the explanatory paradigm should be
changed from a strong emphasis on causal role of inflammation in schizophrenia to the recognition that the observed
immune dysfunction may be related to other factors, such as
obesity and psychological stress. Visceral fat depots (32)
and adipocyte hypertrophy (33) have been linked to a
higher degree of inflammation. It has been observed that,
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